Fresenius Medical Care

620

$32.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-0.19%) Today

$0.00 (0.00%) As of 4:14 PM EDT after-hours

Why Robinhood?

You can buy or sell FMS and other stocks, options, ETFs, and crypto commission-free!

About FMS

Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. Read More It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

CEO

Rice Powell

Employees

—

Headquarters

Bad Homburg, Hessen

Founded

2006

Market Cap

19.25B

Price-Earnings Ratio

14.55

Dividend Yield

1.40

Average Volume

771.09K

High Today

$32.67

Low Today

$32.09

Open Price

$32.49

Volume

372.71K

52 Week High

$42.75

52 Week Low

$29.17

Collections

FMS News

New York TimesApr 1

Fresenius Medical Care Working With Dialysis Providers in U.S. to Tackle Coronavirus

BERLIN — Fresenius Medical Care (FMC) on Wednesday said it was working with other dialysis providers to provide care in isolation for people with kidney problem

ReutersMar 31

BRIEF-Cytosorb Gets Marketing Approval In Mexico

March 31 (Reuters) - Cytosorbents Corp: * CYTOSORB® RECEIVES MARKETING APPROVAL IN MEXICO WITH COMMERCIALIZATION TO COMMENCE WITH PARTNER FRESENIUS MEDICAL CAR

BenzingaMar 31

CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care

MONMOUTH JUNCTION, N.J., March 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO) a critical care immunotherapy leader commercializing its CytoSorb